A Hidden Role of the Inactivated FANCD2: Upregulating ΔNp63

被引:12
作者
Panneerselvam, Jayabal [1 ]
Pickering, Anna [1 ]
Zhang, Jun [2 ]
Wang, Hong [2 ]
Tian, Hui [1 ,3 ]
Zheng, Junnian [3 ]
Fei, Peiwen [1 ]
机构
[1] Univ Hawaii, Ctr Canc, Honolulu, HI 96822 USA
[2] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA
[3] Xuzhou Med Coll, Jiangsu Key Lab Biol Canc Therapy, Xuzhou, Peoples R China
关键词
P63; Fanconi Anemia tumor supressor pathway; oncogene delta N p63; FANCD2; tumorigenicity; transactivation; DAMAGE RESPONSE NETWORK; FANCONI-ANEMIA; P63; CANCER; CISPLATIN; PATHWAY; REPLICATION; DEGRADATION; SUPPRESSION; EXPRESSION;
D O I
10.18632/oncotarget.1217
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A compromised Fanconi Anemia (FA) signaling pathway, often resulting from an inactivated FANCD2, was recently recognized to contribute to the development of non-FA human tumors. However, it is largely unknown as to how an impaired FA pathway or an inactivated FANCD2 promotes tumorigenesis. Here we unexpectedly found that Delta Np63 mRNA was expressed at high levels in human cancer cells carrying an impaired FA pathway compared to the corresponding control cells carrying an intact FA pathway. This observation was recapitulated upon conditionally managing the status of FANCD2 monoubiquitination / activation in 293T cells. Importantly, Delta Np63 elevation upon FANCD2 inactivation was confirmed in human fibroblasts derived from FA patients. Moreover, we have identified a 189 bp DNA fragment downstream of the Delta Np63 promoter (P2) that can mediate the upregulation of Delta Np63 by an inactivated FANCD2, and determined that elevated Delta Np63 is high enough to promote cancer cell proliferation and metastasis. In vivo, the elevation of FAVL, a tumor promotion factor that inhibits FANCD2 activation, was found to be positively associated with Delta Np63 expression in human cancer tissues. Collectively, these results document a novel role of an inactivated FANCD2 in upregulating Delta Np63, advancing our understanding of how an impaired FA pathway contributes to the pathogenesis of human cancer.
引用
收藏
页码:1416 / 1426
页数:11
相关论文
共 44 条
  • [1] p63 the guardian of human reproduction
    Amelio, Ivano
    Grespi, Francesca
    Annicchiarico-Petruzzelli, Margherita
    Melino, Gerry
    [J]. CELL CYCLE, 2012, 11 (24) : 4545 - 4551
  • [2] Combinatorial drug screening identifies compensatory pathway interactions and adaptive resistance mechanisms
    Axelrod, Mark
    Gordon, Vicki L.
    Conaway, Mark
    Tarcsafalvi, Adel
    Neitzke, Daniel J.
    Gioeli, Daniel
    Weber, Michael J.
    [J]. ONCOTARGET, 2013, 4 (04) : 622 - 635
  • [3] Genetic basis of Fanconi anemia
    Bagby, GC
    [J]. CURRENT OPINION IN HEMATOLOGY, 2003, 10 (01) : 68 - 76
  • [4] Fanconi anemia
    Bagby, Grover C.
    Alter, Blanche P.
    [J]. SEMINARS IN HEMATOLOGY, 2006, 43 (03) : 147 - 156
  • [5] A new development in DNA repair modulation Discovery of a BLM helicase inhibitor
    Banerjee, Taraswi
    Aggarwal, Monika
    Brosh, Robert M., Jr.
    [J]. CELL CYCLE, 2013, 12 (05) : 713 - 714
  • [6] Ras inhibition boosts galectin-7 at the expense of galectin-1 to sensitize cells to apoptosis
    Barkan, Batya
    Cox, Adrienne D.
    Kloog, Yoel
    [J]. ONCOTARGET, 2013, 4 (02) : 256 - 268
  • [7] Depletion of the receptor for advanced glycation end products (RAGE) sensitizes towards apoptosis via p53 and p73 posttranslational regulation
    Brune, M.
    Mueller, M.
    Melino, G.
    Bierhaus, A.
    Schilling, T.
    Nawroth, P. P.
    [J]. ONCOGENE, 2013, 32 (11) : 1460 - 1468
  • [8] Epigenetic control of an oncogenic microRNA, miR-155, by BRCA1
    Chang, Suhwan
    Sharan, Shyam K.
    [J]. ONCOTARGET, 2012, 3 (01) : 5 - 6
  • [9] Acetylation of the Cell-Fate Factor Dachshund Determines p53 Binding and Signaling Modules in Breast Cancer
    Chen, Ke
    Wu, Kongming
    Gormley, Michael
    Ertel, Adam
    Wang, Jing
    Zhang, Wei
    Zhou, Jie
    DiSante, Gabriele
    Li, Zhiping
    Rui, Hallgeir
    Quong, Andrew A.
    McMahon, Steven B.
    Deng, Haiteng
    Lisanti, Michael P.
    Wang, Chenguang
    Pestell, Richard G.
    [J]. ONCOTARGET, 2013, 4 (06) : 923 - 935
  • [10] Chiarini F, 2012, ONCOTARGET, V3, P1615